Divalproex Sodium Tablet, Delayed Release
Product Images NDC 50090-7635

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 50090-7635). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907635)

Label for Divalproex Sodium 125 mg delayed-release oral tablets, packaged by A-S Medication Solutions, Libertyville, IL. The label indicates the product NDC 50090-7635, with 30 tablets per package, storage instructions to keep the product at 68 to 77 degrees F, and a note that each delayed-release tablet contains divalproex sodium equivalent to valproic acid 125 mg.*

FDA Label Image

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)

A bar graph labeled Figure 1 comparing two studies. Each study shows percentage values for PBO and DVPX groups. Study 1 (YMRS) shows 26% for PBO and 60% for DVPX. Study 2 (MRS) shows 29% for PBO and 58% for DVPX. The y-axis is percentage from 0% to 70%.*

FDA Label Image

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)

A percent reduction in CPS rate chart comparing Divalproex Sodium (DVPX) and placebo across patient populations. The x-axis shows percent of patients (100 to 0), and the y-axis shows percent reduction in CPS rate from -100% to 100%, with annotations indicating improvement above zero and worsening below zero. Two curves display DVPX and placebo response trends.*

FDA Label Image

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)

A cumulative distribution plot labeled Figure 3 showing percentage reduction in CPS rate versus percentage of patients for high dose and low dose groups. The y-axis ranges from -100% to 100% indicating worsening to improvement, with a midline at 0% for no change. Two curves represent high dose (solid line) and low dose (dashed line) patient responses.*

FDA Label Image

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)

A bar chart titled 'Figure 4 Mean 4-week Migraine Rates' comparing migraine rates over four weeks between placebo and Divalproex Sodium (DVPX) across two studies. The y-axis represents migraine rates ranging from 0 to 6. In both Study 1 and Study 2, bars show lower migraine rates for Divalproex Sodium compared to placebo.*

FDA Label Image

Spl-divalproex-structure (Spl Divalproex Structure)

Chemical structure diagram of divalproex sodium, showing its molecular components and arrangement with sodium ion and organic groups typically representing the active ingredient in the drug Divalproex Sodium.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.